The glucoregulatory benefits of glucagon-like Peptide-1 (7-36) amide infusion during intensive insulin therapy in critically Ill Surgical Patients: A pilot study

Critical Care Medicine

Volumn 42, Issue 3, 2014, Pages 638-645

  Galiatsatos, Panagis ^a   Gibson, B Robert ^a   Rabiee, Atoosa ^a   Carlson, Olga ^b   Egan, Josephine M ^b   Shannon, Richard P ^c   Andersen, Dana K ^a   Elahi, Dariush ^c  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

GLP 1 (7 36) amide; hypoglycemia; intensive insulin therapy; surgical intensive care unit

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CRITICAL ILLNESS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCAGON-LIKE PEPTIDE 1; HOSPITAL MORTALITY; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; INSULIN; INTENSIVE CARE; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PATIENT SAFETY; PILOT PROJECTS; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84894427111     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000000035     Document Type: Article

References (29)

1. van den Berghe G, Wouters P, Weekers F, et al: Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345:1359-1367
2. Aragon D: Evaluation of nursing work effort and perceptions about blood glucose testing in tight glycemic control. Am J Crit Care 2006; 15:370-377
3. Finfer S, Chittock DR, Su SY, et al: Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360:1283-1297
4. American Diabetes Association, Endocrinologists AAoC: Joint Statement from American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on intensive versus conventional glucose control in critically ill patients. 2009. Available at: http://www.diabetes.org/for-media/pr- NICE-SUGAR-study.jsp. Accessed April 6, 2009
5. The Endocrine Society: The Endocrine Society suggests tailored approach to glycemic control in response to the NICESUGAR Study published this week in the New England Journal of Medicine. 2009. Available at: http://www.endo- society.org/ media/press/2008/Society-SuggestsTailoredApproachtoGlycem icControlinResponsetotheNICE-SUGAR.cfm. Accessed April 7, 2009
6. Frezza EE, Wachtel MS, Chiriva-Internati M: The multiple faces of glucagon-like peptide-1-obesity, appetite, and stress: What is next? A review. Dig Dis Sci 2007; 52:643-649
7. Elahi D, Egan JM, Shannon RP, et al: GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide. Obesity (Silver Spring) 2008; 16:1501-1509
8. Prigeon RL, Quddusi S, Paty B, et al: Suppression of glucose production by GLP-1 independent of islet hormones: A novel extrapancreatic effect. Am J Physiol Endocrinol Metab 2003; 285:E701-E707
9. Abu-Hamdah R, Rabiee A, Meneilly GS, et al: Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 2009; 94:1843-1852
10. Nauck MA, Heimesaat MM, Behle K, et al: Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002; 87:1239-1246
11. Kieffer TJ, Habener JF: The glucagon-like peptides. Endocr Rev 1999; 20:876-913
12. Elahi D, McAloon-Dyke M, Fukagawa NK, et al: The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 1994; 51:63-74
13. Zander M, Madsbad S, Madsen JL, et al: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study. Lancet 2002; 359:824-830
14. Meneilly GS, Greig N, Tildesley H, et al: Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. Diabetes Care 2003; 26:2835-2841
15. Nikolaidis LA, Elahi D, Hentosz T, et al: Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004; 110:955-961
16. Gibson BR, Galiatsatos P, Rabiee A, et al: Intensive insulin therapy confers a similar survival benefit in the burn intensive care unit to the surgical intensive care unit. Surgery 2009; 146:922-930
17. Egi M, Bellomo R, Stachowski E, et al: Hypoglycemia and outcome in critically ill patients. Mayo Clin Proc 2010; 85:217-224
18. Meyfroidt G, Keenan DM, Wang X, et al: Dynamic characteristics of blood glucose time series during the course of critical illness: Effects of intensive insulin therapy and relative association with mortality. Crit Care Med 2010; 38:1021-1029
19. Mssig K, Onc A, Lindauer P, et al: Effects of intravenous glucagonlike peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes. Am J Cardiol 2008; 102:646-647
20. Wiener RS, Wiener DC, Larson RJ: Benefits and risks of tight glucose control in critically ill adults: A meta-Analysis. JAMA 2008; 300:933-944
21. Marik PE, Preiser JC: Toward understanding tight glycemic control in the ICU: A systematic review and metaanalysis. Chest 2010; 137:544-551
22. Van den Berghe G: Intensive insulin therapy in the ICU-reconciling the evidence. Nat Rev Endocrinol 2012; 8:374-378
23. Meier JJ, Weyhe D, Michaely M, et al: Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Crit Care Med 2004; 32:848-851
24. Nikolaidis LA, Mankad S, Sokos GG, et al: Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004; 109:962-965
25. Sourij H, Schmlzer I, Kettler-Schmut E, et al: Efficacy of a continuous GLP-1 infusion compared with a structured insulin infusion protocol to reach normoglycemia in nonfasted type 2 diabetic patients: A clinical pilot trial. Diabetes Care 2009; 32:1669-1671
26. Deane AM, Chapman MJ, Fraser RJ, et al: The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: A randomised double-blind placebo-controlled cross over study. Crit Care 2009; 13:R67
27. Sokos GG, Bolukoglu H, German J, et al: Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007; 100:824-829
28. Kovalaske MA, Gandhi GY: Incretins in the ICU: Is insulin on its way out? Crit Care 2009; 13:161
29. Pinelli NR, Jones MC, Monday LM, et al: Exogenous glucagonlike peptide-1 for hyperglycemia in critically ill patients. Ann Pharmacother 2012; 46:124-129